Neoadjuvant giredestrant plus palbociclib (P) vs. anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2-eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study

被引：0
|
作者：
Park, Yeon Hee
Quiroga, Vanesa
Fasching, Peter A.
Bardia, Aditya
Lopez-Valverde, Vanesa
Crnjevic, Tanja Badovinac
Steinseifer, Jutta
Devine, Jacob
Hurvitz, Sara A.
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] GEICAM Spanish Breast Canc Grp, Madrid, Spain
[3] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Comprehens Canc Ctr CCC Erlangen EMN, Erlangen, Germany
[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Genentech Inc, South San Francisco, CA USA
[7] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
591
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A randomized, double-blind phase II trial of exemestane with or without MM-121 in postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER plus ) and/or progesterone receptor-positive (PR+), HER2-negative breast cancer.
    Moyo, V. M.
    Higgins, M. J.
    Aravelo-Araujo, R.
    Iannotti, N.
    Charu, V.
    Dhindsa, N.
    Goss, P. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Activity and biomarker analyses from a phase Ia/b study of giredestrant (GDC-9545; G) with or without palbociclib (palbo) in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer (ER+/HER2-LA/mBC)
    Turner, Nicolas C.
    Loi, Sherene
    Moore, Heather M.
    Chang, Ching-Wei
    Eng-Wong, Jennifer
    Bardia, Aditya
    Boni, Valentina
    Sohn, Joohyuk
    Jhaveri, Komal L.
    Lim, Elgene
    CANCER RESEARCH, 2022, 82 (04)
  • [43] LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer
    Saura, Cristina
    de Azambuja, Evandro
    Dubsky, Peter
    Oliveira, Mafalda
    Saini, Kamal S.
    Fes, Christian
    Lin, Ray S.
    Wilson, Timothy R.
    Fredickson, Jill
    Parmar, Hema
    Hsu, Jerry Y.
    Piccard, Martine
    Gnant, Michael
    Baselga, Jose
    CANCER RESEARCH, 2015, 75
  • [44] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study
    Ibrahim, Nuhad K.
    Hamilton, Erika P.
    Kim, Sung-Bae
    Im, Young-Hyuck
    Segui, Elia
    Garcia-Saenz, Jose A.
    Di Sanzo, Alessandro
    Vallespir, Bartomeu Piza
    Lizarbe, Manuel Dominguez
    Wasserman, Tomer
    Theall, Kathy Puyana
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib plus letrozole vs placebo plus letrozole in the phase III MONALEESA-2 study
    Blackwell, Kimberly L.
    Paluch-Shimon, Shani
    Campone, Mario
    Conte, Pierfranco
    Petrakova, Katarina
    Favret, Anne
    Blau, Sibel
    Beck, J. Thaddeus
    Miller, Michelle
    Sutradhar, Santosh
    Monaco, Mauricio
    Burris, Howard A.
    CANCER RESEARCH, 2018, 78 (04)
  • [46] Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
    Manuel Ruíz-Borrego
    Angel Guerrero-Zotano
    Begoña Bermejo
    Manuel Ramos
    Josefina Cruz
    Jose Manuel Baena-Cañada
    Beatriz Cirauqui
    Álvaro Rodríguez-Lescure
    Emilio Alba
    Noelia Martínez-Jáñez
    Montserrat Muñoz
    Silvia Antolín
    Isabel Álvarez
    Sonia Del Barco
    Elena Sevillano
    José Ignacio Chacón
    Antonio Antón
    María José Escudero
    Victoria Ruiz
    Eva Carrasco
    Miguel Martín
    Breast Cancer Research and Treatment, 2019, 177 : 115 - 125
  • [47] acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).
    Martin, Miguel
    Lim, Elgene
    Mac Gregor, Mariana Chavez
    Shivhare, Mahesh
    Ross, Graham
    Patre, Monika
    Roncoroni, Laura
    Louka, Maria
    Sohn, Joohyuk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer
    Oliveira, M.
    de Azambuja, E.
    Saura, C.
    Dubsky, P.
    Zardavas, D.
    Fesl, C.
    Bardia, A.
    Soberino, J.
    Gil, E. Ciruelos
    Ng, V.
    Fredrickson, J.
    Stout, T. J.
    Singel, S. M.
    Hsu, J. Y.
    Piccart, M.
    Gnant, M.
    Baselga, J.
    CANCER RESEARCH, 2016, 76
  • [49] A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)
    Dickler, Maura N.
    Villanueva, Rafael
    Fidalgo, Jose Alejandro Perez
    Mayer, Ingrid A.
    Boni, Valentina
    Winer, Eric P.
    Hamilton, Erika P.
    Bellet, Meritxell
    Urruticoechea, Ander
    Gonzalez-Martin, Antonio
    Cortes, Javier
    Martin, Miguel
    Giltnane, Jennifer
    Gates, Mary
    Cheeti, Sravanthi
    Fredrickson, Jill
    Wang, Xiaojing
    Friedman, Lori S.
    Spoerke, Jill M.
    Metcalfe, Ciara
    Liu, Lichuan
    Li, Robert
    Morley, Roland
    McCurry, Ursula
    Chan, Iris T.
    Mueller, Lars
    Milan, Sandra
    Lauchle, Jennifer
    Humke, Eric W.
    Bardia, Aditya
    CANCER RESEARCH, 2018, 78 (04)
  • [50] Interim analysis (IA) of the giredestrant (G) plus samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
    Oliveira, M.
    Gion Cortes, M.
    Jung, K. H.
    Bermejo, B.
    Hurvitz, S. A.
    Sadeghi, S.
    Wander, S.
    Im, S-A.
    Gal-Yam, E.
    Zhu, J.
    Schwab, R.
    Ngo, H.
    Collier, A.
    Cannon, M.
    Cahuzac, C.
    Moreno, P. D. Perez
    Mcintosh, S.
    Saavedra Serrano, C.
    Sonnenblick, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S370 - S371
12345